Table 3. Summary of methylation changes following treatment with different drug regimens.
| AML – XG1 | Total number of CpG sites changed | % of total CpG sites changed | Hypomethylated | Hypermethylated | Ratio of hypomethylated to hypermethylated changes | Median change in Beta Value |
| PBS vs DAC | 17275 | 3.8 | 17258 | 17 | 1015∶1 | −0.032 |
| PBS vs Ara-C | 122690 | 26.4 | 85702 | 36988 | 2∶1 | 0.025 |
| PBS vs D+A | 9906 | 2.0 | 5223 | 4683 | 1∶1 | 0.015 |
| PBS vs A/D | 164220 | 34.4 | 156585 | 7635 | 21∶1 | −0.028 |
| PBS vs D/A | 162719 | 35.7 | 123987 | 38732 | 3∶1 | −0.064 |
| AML - XG2 | ||||||
| PBS vs DAC | 14879 | 3.0 | 14857 | 22 | 675∶1 | −0.042 |
| PBS vs Ara-C | 156544 | 33.3 | 118532 | 38012 | 3∶1 | 0.04 |
| PBS vs D+A | 12809 | 2.8 | 9611 | 3198 | 3∶1 | 0.0255 |
| PBS vs A/D | 111255 | 22.9 | 102419 | 8836 | 12∶1 | −0.047 |
| PBS vs D/A | 170595 | 35.8 | 110686 | 59909 | 2∶1 | −0.078 |
| AML - XG3 | ||||||
| PBS vs DAC | 10304 | 2.2 | 10290 | 14 | 735∶1 | −0.0485 |
| PBS vs Ara-C | 137804 | 28.9 | 84792 | 53012 | 2∶1 | 0.011 |
| PBS vs D+A | 8831 | 1.9 | 3433 | 5398 | 1∶1 | 0.005 |
| PBS vs A/D | 99420 | 21.3 | 93227 | 6193 | 15∶1 | −0.0195 |
| PBS vs D/A | 204784 | 43.2 | 143348 | 61436 | 2∶1 | −0.092 |
For each xenograft, the number of hypomethylation and hypermethylation changes as well as the median change in beta value following treatment with each drug regimen. Differentially methylated CpG sites were identified using Genome Studio; results were filtered to retain CpG in which the change in beta values between PBS and drug treated samples was >±0.2.